Cite
MLA Citation
A. Gibb et al.. “RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY).” Hematological oncology, vol. 35, n.d., pp. 80–81. http://access.bl.uk/ark:/81055/vdc_100047525806.0x000036